{"ticker": {"uuid": "e0bb6dc2-9c6a-49e0-ad0c-3d054544869d", "symbol": "BBIO", "name": "BridgeBio Pharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BBIO6017175 Bond Risk Profile", "summary": "This page provides a risk profile for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond, identified by FINRA BBIO6017175. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliabilit", "url": "https://www.tradingview.com/symbols/FINRA-BBIO6017175/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T05:43:32", "published_display": "14 Jul 2026 05:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma(BBIO.US) Director Sells US$13.16 Million in Common Stock", "summary": "A director at BridgeBio Pharma (BBIO.US) recently sold common stock valued at approximately US$13.16 million. This transaction involved the sale of 468,546 shares at an average price of US$28.09 per share. Following this sale, the director still retains 5,798,064 shares of the co", "url": "https://www.moomoo.com/news/post/72879753/bridgebio-pharma-bbious-director-sells-us-13-16-million-in", "source_name": "Moomoo", "published_at": "2026-07-14T02:43:32", "published_display": "14 Jul 2026 02:43", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBIO6336503 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (BBIO6336503). It outlines details such as the issuer, issue date, maturity date, outstanding amount, face value, and coupon rate. The bond's profile highlights that BridgeBio Pharma, Inc. foc", "url": "https://www.tradingview.com/symbols/FINRA-BBIO6336503/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T00:43:32", "published_display": "14 Jul 2026 00:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 BridgeBio Pharma Inc For: 13 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNXy1zcEl2aUpZeERvR3pwSjF6eDZSMTdmZ0lvQUw3OWZpcnFlX0FEQWNpNlpYT2VZTC1JYURPS0JsMFBXZF83aEx1bF9KdmQ4VU1QZFhtSUxzdTNWbUNDaERqQjBQU3l2VllwelV6Rk4tN2J0dUZFSlBULUJPa1F4WG1WcXNHQW1zUVYyT2g3YWxQakY0N3NGQmYxa2pKcmZ1SHc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-13T20:53:02+00:00", "published_display": "13 Jul 2026 20:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma director Jennifer E. Cook sells $13.16m in shares", "summary": "Jennifer E. Cook, a director at BridgeBio Pharma, sold shares totaling $13.16 million after exercising stock options, leading to a net direct holding of 8,383 shares. These transactions were part of a Rule 10b5-1 sales plan. The company's stock is trading near its 52-week high an", "url": "https://www.investing.com/news/insider-trading-news/bridgebio-pharma-director-jennifer-e-cook-sells-1316m-in-shares-93CH-4789350", "source_name": "Investing.com", "published_at": "2026-07-13T20:40:53", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) director sells 17167.0000 shares after option exercise", "summary": "BridgeBio Pharma director Andrea Ellis reported an exercise-and-sale sequence on July 9, 2026, involving 17,167 shares of common stock. She exercised stock options at $16.75 per share and subsequently sold all 17,167 shares at $84.00 per share under a Rule 10b5-1 sales plan estab", "url": "https://www.stocktitan.net/sec-filings/BBIO/form-4-bridge-bio-pharma-inc-insider-trading-activity-3040c4ee941b.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:40:52", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma director Andrea Ellis sells $1.44m in stock", "summary": "BridgeBio Pharma director Andrea Ellis sold $1.44 million worth of company common stock on July 9, 2026, as part of a Rule 10b5-1 sales plan adopted in December 2025. This transaction followed her exercise of stock options for 17,167 shares at $16.75 per share. The stock is curre", "url": "https://www.investing.com/news/insider-trading-news/bridgebio-pharma-director-andrea-ellis-sells-144m-in-stock-93CH-4789354", "source_name": "Investing.com", "published_at": "2026-07-13T20:40:52", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (NASDAQ: BBIO) director exercises options, sells 148,589 shares", "summary": "BridgeBio Pharma director Jennifer E. Cook exercised stock options for 148,589 shares and then sold an equal number of shares in open-market transactions on July 9, 2026. The sales, totaling approximately $13.16 million, were conducted pursuant to a pre-arranged Rule 10b5-1 sales", "url": "https://www.stocktitan.net/sec-filings/BBIO/form-4-bridge-bio-pharma-inc-insider-trading-activity-4f0182033798.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:40:52", "published_display": "13 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US10806XAH5 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (US10806XAH5), traded on the Frankfurt Stock Exchange. It details the bond's coupon rate, issue date, maturity date, and face value, along with a brief description of BridgeBio Pharma, Inc. Th", "url": "https://www.tradingview.com/symbols/FWB-US10806XAH5/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T19:40:52", "published_display": "13 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BridgeBio: \"Strong Buy\" Attruby Differentiation And Several NDA Submissions In Play (NASDAQ:BBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcndka2Q2bWRDTWdyTVRFY1VfUk0tUEV3VzZoVnVta0ZSR2pFVWpCSjJISmROZlNLeU1fZzhxekVDRWd4dzUwcThTU0hVRTJTeE1OVzFrTU40aDQzbWpib2RiZThRcElDa2FfS01HY09tcDlTWW9HckEyaGNnTnI3amRfeDdlWV9FY0dIRGZ2bTBVVGI1Q1JBeFI5RXlzRDUzYkRQMXlnc3M3dUVHeXBJcGxSWldEM3VfU3RBOWdn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-12T13:55:00+00:00", "published_display": "12 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Following Wainua Trial Setback Still Looks Undervalued", "summary": "BridgeBio Pharma (BBIO) stock experienced volatility after AstraZeneca's Wainua trial setback, impacting expectations for Attruby. Despite this, the company's valuation against an average analyst target and intrinsic value estimates suggests it may still be undervalued, driven by", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/bridgebio-pharma-bbio-following-wainua-trial-setback-still-l", "source_name": "Simply Wall Street", "published_at": "2026-07-12T12:10:16", "published_display": "12 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "BridgeBio Pharma, Inc. announced equity grants to 37 new employees, totaling 83,283 restricted stock units of the Company\u2019s common stock. These grants were approved by the compensation committee on July 7, 2026, and are considered inducement material for employment, compliant wit", "url": "https://www.manilatimes.net/2026/07/11/tmt-newswire/globenewswire/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2382605", "source_name": "The Manila Times", "published_at": "2026-07-11T19:39:53", "published_display": "11 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Global\u2019s BridgeBio Pharma (NASDAQ: BBIO) stake moves just under 5%", "summary": "Viking Global Investors and its affiliated entities have reported that their beneficial ownership in BridgeBio Pharma (NASDAQ: BBIO) has fallen just under 5%, specifically to 4.9951% as of July 9, 2026. This change was disclosed in an Amendment No. 12 to their Schedule 13D filing", "url": "https://www.stocktitan.net/sec-filings/BBIO/schedule-13d-a-bridge-bio-pharma-inc-amended-major-shareholder-report-c7bd1b05c571.html", "source_name": "Stock Titan", "published_at": "2026-07-11T13:09:43", "published_display": "11 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio (BBIO) Q1 2025 earnings summary", "summary": "BridgeBio's Q1 2025 results show strong initial sales for Attruby and significant total revenue. The company reported a widened net loss due to increased SG&A and interest expenses but maintains a robust pipeline with several phase three readouts expected within the next year. Wi", "url": "https://quartr.com/events/bridgebio-pharma-inc-bbio-q1-2025_3PPZGPUJ", "source_name": "Quartr", "published_at": "2026-07-11T00:40:57", "published_display": "11 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio hands new hires 83,283 stock-unit incentive awards", "summary": "BridgeBio Pharma (Nasdaq: BBIO) reported that its board compensation committee approved inducement equity grants of restricted stock units (RSUs) to 37 new employees, totaling 83,283 common shares, on July 7, 2026. These RSUs will vest one-fourth on August 16, 2027, with the rema", "url": "https://www.stocktitan.net/news/BBIO/bridge-bio-pharma-reports-inducement-grants-under-nasdaq-listing-i3iu9i3rwvsv.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:13", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High", "summary": "BridgeBio Pharma's (BBIO) stock surged to a 52-week high after AstraZeneca's (AZN) late-stage clinical trial for its ATTR-CM drug, Wainua, failed to meet its primary endpoint. This setback is seen as beneficial for BridgeBio's Attruby, its sole marketed drug for ATTR-CM, strength", "url": "https://www.tradingview.com/news/zacks:b3374f1cf094b:0-how-a-rival-s-clinical-setback-sent-bbio-stock-to-a-52-week-high/", "source_name": "TradingView", "published_at": "2026-07-10T16:39:13", "published_display": "10 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Is Up 16.8% After Phase 3 Infigratinib Win And $934M Raise", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bridgebio-pharma-bbio-16-8-121349835.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T12:13:49+00:00", "published_display": "10 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?", "summary": "BridgeBio Pharma (BBIO) is experiencing a powerful transition, with its lead drug Attruby driving significant revenue growth and three more drugs in the pipeline. Despite a high market valuation and lack of profitability, the company is well-capitalized to pursue its ambitious la", "url": "https://www.trefis.com/stock/bbio/articles/606603/beyond-the-breakout-drug-is-bridgebio-pharma-stock-a-buy-on-its-next-act/2026-07-10", "source_name": "Trefis", "published_at": "2026-07-10T12:39:13", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNUjlDNWpKRXFJX0tSMm1WMWJMYmFLa09lcXFCLUpacmFNNG1fVjdWU2d5M3lRN2laWjFHWDFNWlFlY2twMHRWQTBDYVoyZU42ZkVQQ0ZpamhyMHl2S1Ziek1ldnl3aG9wVGg1RDlCVnVVS3hzTFZqRTVneGUyaDlfOHlFal9ScGdsWnV1eVNFcGQ0eFRkWG5IUzNyQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T09:33:00+00:00", "published_display": "10 Jul 2026 09:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio (BBIO) Q3 2025 earnings summary", "summary": "BridgeBio (BBIO) reported strong Q3 2025 earnings, with total revenue reaching $120.7 million, primarily driven by the successful commercial launches of Attruby and Beyonttra. The company maintained a robust financial position with $645.9 million in cash and plans for NDA filings", "url": "https://quartr.com/events/bridgebio-pharma-inc-bbio-q3-2025_3PPZGpsg", "source_name": "Quartr", "published_at": "2026-07-10T02:39:13", "published_display": "10 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio stock jumps after rival heart drug fails key trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNUnhHaGczS3JXemNJejFpV2NxTjRuQW5Zc0NLUmhmSUZIbFdBUHo2ZGt1TnFFY1BkVDJtd0xmMGt0TEVtRDhKN1NlTDNoMGpYYTdHbUZScnRGZVQ4UVVJd055cU4wdGdVUnJZak5VTGlfTUxkczh6ZU5UdnR5aFY5RThacGNxQjZXaEd5OVNOMXJWcUIyRWRpN2hB?oc=5", "source_name": "Market source", "published_at": "2026-07-09T23:38:00+00:00", "published_display": "09 Jul 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma BBIO Jumps As Infigratinib Data, $1B Raise Fire Up Bulls", "summary": "BridgeBio Pharma (BBIO) shares surged over 15% following positive Phase 3 trial results for its drug infigratinib in pediatric achondroplasia, which also secured publication in the New England Journal of Medicine. The company plans FDA and EMA filings in 2026 for a potential U.S.", "url": "https://www.timothysykes.com/news/bridgebio-pharma-inc-bbio-news-2026_07_09-3/", "source_name": "www.timothysykes.com", "published_at": "2026-07-09T20:43:55", "published_display": "09 Jul 2026 20:43", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] BridgeBio Pharma, Inc. SEC Filing", "summary": "This article announces a Form 144 SEC filing by BridgeBio Pharma, Inc. (BBIO). The filing details a proposed sale of 17,167 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,442,028. The shares were acquired on J", "url": "https://www.stocktitan.net/sec-filings/BBIO/144-bridge-bio-pharma-inc-sec-filing-615bd79faaa2.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:43:55", "published_display": "09 Jul 2026 19:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma BBIO Jumps On Trial Win And $1B Raise", "summary": "BridgeBio Pharma (BBIO) shares jumped over 13% following positive Phase 3 clinical trial results for its oral infigratinib in pediatric achondroplasia, which showed statistically significant improvements in body proportionality and arm span. The company also secured up to $1 bill", "url": "https://stockstotrade.com/news/bridgebio-pharma-inc-bbio-news-2026_07_09-2/", "source_name": "StocksToTrade", "published_at": "2026-07-09T16:43:55", "published_display": "09 Jul 2026 16:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma stock reaches all-time high at 86.0 USD", "summary": "BridgeBio Pharma Inc. (BBIO) stock hit an all-time high of $86.00, pushing its market capitalization to $15.4 billion, reflecting a significant 69.29% increase over the past year. This milestone comes after recent developments including a $1 billion preferred equity investment an", "url": "https://www.investing.com/news/company-news/bridgebio-pharma-stock-reaches-alltime-high-at-860-usd-93CH-4784266", "source_name": "Investing.com", "published_at": "2026-07-09T14:43:55", "published_display": "09 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma Up Over 14%, on Track for Record High Close -- Data Talk", "summary": "BridgeBio Pharma's stock is up over 14% and is on track for a record high close. This significant jump suggests positive market reaction, likely driven by recent company developments or news.", "url": "https://www.moomoo.com/news/post/72722637/bridgebio-pharma-up-over-14-on-track-for-record-high", "source_name": "Moomoo", "published_at": "2026-07-09T13:43:55", "published_display": "09 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Is Up 5.1% After Kidney Data Boost Attruby And Infigratinib Advances", "summary": "BridgeBio Pharma reported positive Phase 3 data for infigratinib and new post-hoc analyses suggesting kidney-protective effects of acoramidis (Attruby), alongside securing up to $1 billion in preferred equity financing. These developments aim to expand Attruby\u2019s profile and advan", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/bridgebio-pharma-bbio-is-up-51-after-kidney-data-boost-attru/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-09T13:43:55", "published_display": "09 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback", "summary": "Shares of BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) surged by approximately 15% and 18%, respectively, after AstraZeneca's (AZN) and Ionis Pharma's (IONS) late-stage trial for a competing transthyretin amyloid cardiomyopathy (ATTR-CM) treatment failed. This setback for ri", "url": "https://www.gurufocus.com/news/8951118/bridgebio-pharma-bbio-and-alnylam-pharma-alny-surge-after-astrazeneca-trial-setback", "source_name": "GuruFocus", "published_at": "2026-07-09T12:27:46", "published_display": "09 Jul 2026 12:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead", "summary": "S&P 500 futures are rising in premarket trading, with Alnylam Pharmaceuticals (ALNY) and BridgeBio Pharma (BBIO) leading the gains. ALNY was up 18.4% and BBIO was up 14.0% ahead of the U.S. stock market open.", "url": "https://www.barrons.com/articles/s-p-500-futures-climb-in-premarket-trading-alnylam-pharmaceuticals-bridgebio-pharma-lead-504d6635", "source_name": "Barron's", "published_at": "2026-07-09T11:39:46", "published_display": "09 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is BridgeBio Pharma stock surging today?", "summary": "BridgeBio Pharma's stock surged 12.4% after a rival heart disease drug from AstraZeneca and Ionis, Wainua, failed its Phase III trial. This failure provides a significant competitive advantage to BridgeBio's oral TTR stabilizer, Attruby, in the ATTR-CM market and reinforces Bridg", "url": "https://www.investing.com/news/stock-market-news/why-is-bridgebio-pharma-stock-surging-today-93CH-4783470", "source_name": "Investing.com", "published_at": "2026-07-09T10:39:46", "published_display": "09 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth", "summary": "BridgeBio Pharma (BBIO) is focusing on rare diseases with a strategy built around new diagnoses and targeted treatments. Its primary revenue driver, Attruby, has seen strong sales and benefits from increased awareness of transthyretin amyloid cardiomyopathy. The company's late-st", "url": "https://www.tradingview.com/news/zacks:ba7af4ddc094b:0-bridgebio-stock-taps-rare-disease-trends-and-new-diagnosis-growth/", "source_name": "TradingView", "published_at": "2026-07-08T16:11:05", "published_display": "08 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts", "summary": "BridgeBio Pharma's (BBIO) stock outlook is transitioning from a launch-focused narrative to one centered on broad commercial execution. Its primary revenue driver, Attruby, generated significant sales in its first full year and continues to grow, while the company plans three new", "url": "https://www.tradingview.com/news/zacks:ef91b97d7094b:0-bridgebio-stock-outlook-hinges-on-attruby-new-drug-catalysts/", "source_name": "TradingView", "published_at": "2026-07-08T16:11:05", "published_display": "08 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9 Green Days In A Row: BridgeBio Pharma Stock Is Up 14%", "summary": "BridgeBio Pharma (BBIO) stock has experienced a nine-day winning streak, gaining 13.5% and adding $1.8 billion to its market value. Despite this momentum and 355.2% revenue growth, the biotech company shows deep losses with an operating margin of -86.9% and a negative P/E multipl", "url": "https://www.trefis.com/stock/bbio/articles/606162/9-green-days-in-a-row-bridgebio-pharma-stock-is-up-14/2026-07-08", "source_name": "Trefis", "published_at": "2026-07-08T10:10:25", "published_display": "08 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio gets $1B from Sixth Street, HCRx for three launches", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNMXBMMkV5V1gxaFJXckFOUHByNXVORG5PcUZ3dUZ0TlMwWmplWVhnSWJUQ2VUeE5DWjk1QWNNb2dRMG5neXIzTUJ2T3lEZlVHRWVKZkNQeVEyWDlaQzFFbWgwYzJad0kyZTFJcW5jVHRUT3dhS1dYbWsyZ1I3Qjc5djlOSF9jX3otV25wRG5iOWZ0ME5iVFpWeTFyMFJSZTBnNzNsdUlNYnVEY0V6QzJLMWNOX1FpRWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BridgeBio Pharma (BBIO) Undervalued As Rare Disease Launch Hopes Face A Rich P/S?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Priority Review Puts BBP-418 And Valuation In Investor Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQUk5laEc1ZXFveDlrall4VTQ1TkY1TV8teU14VTE2RzBVZlZLbUNOcE5SSksybGRjdHZtd0JWcHNFNDF1NWtXd21RUE9lbUgyVjgtRlc5Y0NPNVJIZjJDc2syMElNaFpla3pad2xMbURDY2YxaXVLR0owMThmN2JaM0NmYklsOWl6bEpfQUx0YzlNbVJjQlQ3OGlfVDk2d05EZ1ctaXlVeWFLWFpTd3ZEd3Jkbzd4Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPYXkxMFAzRUI0MHVHeS1nbWVVd3V2YVZ5cmk2TW0tUzFjZzB4N2JseHp4VFFMQ1FvTXAwdGZodkpWeHFjZVNkTXNpTVNhMUwtanRwSnhWbUtuRkJuOHUydHBJVVVlU2IzazF1aXIzZ2MxS0c3RkpJYzBKb3dhdmphcm1hZ1lXaDFaZ0k0alNtSnJGU0NRQmNnV2R6eVllTU1MZW1jUUZOWmdnRkVTUThRY1dVSVZEdUVPSFlkWGVhdFBVWkZ1eHhmZg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At BridgeBio Pharma (BBIO) Valuation After Recent Trading Weakness And Pipeline Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYjVOTDNzcjNHVmZuWW5qcUhRVlhsYWZpQXVvZ1pYLU5DY3hEOWhpRU1BaFVURVhaM0xEeF96UEF4Smt4bUNZdkwtbWdpdXloejJZb0FfLW1QU0xpQUpJYVpJQkJ4ZzZxTE1Bb1pvTHdYTWhTUFdsZTF0aDBnS2wxNDFuUjh6ZGh0ckxHZEg3eDFlM2g5MzJMSjJFbENwc0VnU0xr?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brazil approves BridgeBio\u2019s acoramidis for heart condition", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNVDVJZ2ZOZV9kOUZqb1pjdGloVHZGYUg2WGVMb09BUFR5R3NzakdBRUJ6cE9NYXVhdnpJaWFtbnZoM1l2YzBKV3ZoVFRZLWMwVlRJZUNFWmFkYkljNWhTZU1CZTI1MFRxcng1M1NIUFlkcU9xRzlaaEZjM1hZMGpMdDNDN3V4Sml6WEVJNkgxVUhxbUd3dXBhaEwtR3VZMTFaQk1Gc3Nnc2Y5ZlNQdnRTMlFaSWI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVkZjVlpudHRBREVoMHRocUhPUXEzbG5RQ1FXUDVKQ05BUlJKRWZqM2x1S0o2TmdXZ214UHphcy11RkpRYVB6eEdJNUhjVjR0T3JLWEhBR29oWm1NWUZTMjBra19jcEx0U1BYdlhvM3U1bWctZVpEVVFlRTRqMk9rTDh2eGl6VXgxVDN1ZlE0Mi00cS1OMjFzU2ZIYm9zWnBYUDFURVczMi1fc2JidVg3Ql9JS3JnNHc1V2swclV3ZkI0cm9UQXF3N2xtMEZZaklsR2c?oc=5", "source_name": "Investing.com", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Has BridgeBio Pharma (BBIO) Run Too Far After 112% One Year Share Price Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOVHJVaUF2V0d5MXU1eC1TeDQyQjF3QzNRaGdqTFpRc3piVmNYSE1jbHVzTnBjcXpUUGtCZXN5eno0Ukh1VW5BX2JRejJXTDh4SHhCc0d6YXhHODVSQzAtaFhjZzR4aGpscXdDdzZFSGJFeHBLQVBZM01jdi1lN3VpQXdPc3hYSHBWSGNnU2Zac0pJS3VTdl80cTVQU0d3RGF2OGd3N09xNF83NmlUa0pTT0hPamJlSHlDYlVldkhqOTBkUjVmcC1BaG13TFREWEU3eUJCZnFQSnZ5Q2FQVkgyWEt0VWHSAeoBQVVfeXFMTktrY3JPVm94dURINTEyQ1RRVEZNS2had1otZWNwbkpKSjBJeWdyOHMzX3pSeWF2NnZwSkV4YVRaNWRDZ2NIa1RFaE1ZRVV5M2VwV1RobjdZa0NJMGtEX3gtUlpoUW1ER2xJb0I5Q04wZTJYc29jUGZXTExiT0VTZENZTzNhVXQwdVVSUGxmcTZjMGZVamFNRlNWMDRoMm9KaURVSm0tbHNGakZ3T2JTWU56c0dDbGpnckZSakpTTUwybncwS19kMUFNYjFCUFo2MWZmbWdTcHNYbmZkQUllWVBxeE1vZFFHSS1R?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BoFA Notes BridgeBio Pharma, Inc. (BBIO)\u2019s Upcoming Q4 Earnings May Have Limited Market Impact", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNWWo5YjNhOHVTVENHS2lJVE9VRlRIRTVPM0NYaW5ZSC1BRlVqcVQwbXVfai1yc3FUVkhqX3ItOXRYWkg3ZGM5TFM2TXFNa0R0VmpFRmdvYmFjTmZFVnBuLUdGclFuMFVwZWpfbnVoZDhQZy1Hc1JGTGJOLXd1TDRLcHZpcw?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Has More Room To Run (NASDAQ:BBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9MV2FXcV84YktmSDFSYXFLZUE0bVFwb1JmbTJYcVhZTUQxQ1MyWTVfVGhaSU5SeHBDcUN6S09NQVlQakhHNDR3bnZ2Y3lKQ0RrY0pFYTBSUjRQN21wTXFDejBXMTItSUQ1bjZqN1RCVkZVMFA0SW1qOUc3MA?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BBIO6017175 Bond Risk Profile", "summary": "This page provides a risk profile for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond, identified by FINRA BBIO6017175. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliabilit", "url": "https://www.tradingview.com/symbols/FINRA-BBIO6017175/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-14T05:43:32", "published_display": "14 Jul 2026 05:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma(BBIO.US) Director Sells US$13.16 Million in Common Stock", "summary": "A director at BridgeBio Pharma (BBIO.US) recently sold common stock valued at approximately US$13.16 million. This transaction involved the sale of 468,546 shares at an average price of US$28.09 per share. Following this sale, the director still retains 5,798,064 shares of the co", "url": "https://www.moomoo.com/news/post/72879753/bridgebio-pharma-bbious-director-sells-us-13-16-million-in", "source_name": "Moomoo", "published_at": "2026-07-14T02:43:32", "published_display": "14 Jul 2026 02:43", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BBIO6336503 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (BBIO6336503). It outlines details such as the issuer, issue date, maturity date, outstanding amount, face value, and coupon rate. The bond's profile highlights that BridgeBio Pharma, Inc. foc", "url": "https://www.tradingview.com/symbols/FINRA-BBIO6336503/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T00:43:32", "published_display": "14 Jul 2026 00:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 BridgeBio Pharma Inc For: 13 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNXy1zcEl2aUpZeERvR3pwSjF6eDZSMTdmZ0lvQUw3OWZpcnFlX0FEQWNpNlpYT2VZTC1JYURPS0JsMFBXZF83aEx1bF9KdmQ4VU1QZFhtSUxzdTNWbUNDaERqQjBQU3l2VllwelV6Rk4tN2J0dUZFSlBULUJPa1F4WG1WcXNHQW1zUVYyT2g3YWxQakY0N3NGQmYxa2pKcmZ1SHc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-13T20:53:02+00:00", "published_display": "13 Jul 2026 20:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma director Jennifer E. Cook sells $13.16m in shares", "summary": "Jennifer E. Cook, a director at BridgeBio Pharma, sold shares totaling $13.16 million after exercising stock options, leading to a net direct holding of 8,383 shares. These transactions were part of a Rule 10b5-1 sales plan. The company's stock is trading near its 52-week high an", "url": "https://www.investing.com/news/insider-trading-news/bridgebio-pharma-director-jennifer-e-cook-sells-1316m-in-shares-93CH-4789350", "source_name": "Investing.com", "published_at": "2026-07-13T20:40:53", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) director sells 17167.0000 shares after option exercise", "summary": "BridgeBio Pharma director Andrea Ellis reported an exercise-and-sale sequence on July 9, 2026, involving 17,167 shares of common stock. She exercised stock options at $16.75 per share and subsequently sold all 17,167 shares at $84.00 per share under a Rule 10b5-1 sales plan estab", "url": "https://www.stocktitan.net/sec-filings/BBIO/form-4-bridge-bio-pharma-inc-insider-trading-activity-3040c4ee941b.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:40:52", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma director Andrea Ellis sells $1.44m in stock", "summary": "BridgeBio Pharma director Andrea Ellis sold $1.44 million worth of company common stock on July 9, 2026, as part of a Rule 10b5-1 sales plan adopted in December 2025. This transaction followed her exercise of stock options for 17,167 shares at $16.75 per share. The stock is curre", "url": "https://www.investing.com/news/insider-trading-news/bridgebio-pharma-director-andrea-ellis-sells-144m-in-stock-93CH-4789354", "source_name": "Investing.com", "published_at": "2026-07-13T20:40:52", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (NASDAQ: BBIO) director exercises options, sells 148,589 shares", "summary": "BridgeBio Pharma director Jennifer E. Cook exercised stock options for 148,589 shares and then sold an equal number of shares in open-market transactions on July 9, 2026. The sales, totaling approximately $13.16 million, were conducted pursuant to a pre-arranged Rule 10b5-1 sales", "url": "https://www.stocktitan.net/sec-filings/BBIO/form-4-bridge-bio-pharma-inc-insider-trading-activity-4f0182033798.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:40:52", "published_display": "13 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US10806XAH5 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the BridgeBio Pharma, Inc. 1.75% 01-MAR-2031 bond (US10806XAH5), traded on the Frankfurt Stock Exchange. It details the bond's coupon rate, issue date, maturity date, and face value, along with a brief description of BridgeBio Pharma, Inc. Th", "url": "https://www.tradingview.com/symbols/FWB-US10806XAH5/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-13T19:40:52", "published_display": "13 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio: \"Strong Buy\" Attruby Differentiation And Several NDA Submissions In Play (NASDAQ:BBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPcndka2Q2bWRDTWdyTVRFY1VfUk0tUEV3VzZoVnVta0ZSR2pFVWpCSjJISmROZlNLeU1fZzhxekVDRWd4dzUwcThTU0hVRTJTeE1OVzFrTU40aDQzbWpib2RiZThRcElDa2FfS01HY09tcDlTWW9HckEyaGNnTnI3amRfeDdlWV9FY0dIRGZ2bTBVVGI1Q1JBeFI5RXlzRDUzYkRQMXlnc3M3dUVHeXBJcGxSWldEM3VfU3RBOWdn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-12T13:55:00+00:00", "published_display": "12 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Following Wainua Trial Setback Still Looks Undervalued", "summary": "BridgeBio Pharma (BBIO) stock experienced volatility after AstraZeneca's Wainua trial setback, impacting expectations for Attruby. Despite this, the company's valuation against an average analyst target and intrinsic value estimates suggests it may still be undervalued, driven by", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/bridgebio-pharma-bbio-following-wainua-trial-setback-still-l", "source_name": "Simply Wall Street", "published_at": "2026-07-12T12:10:16", "published_display": "12 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "BridgeBio Pharma, Inc. announced equity grants to 37 new employees, totaling 83,283 restricted stock units of the Company\u2019s common stock. These grants were approved by the compensation committee on July 7, 2026, and are considered inducement material for employment, compliant wit", "url": "https://www.manilatimes.net/2026/07/11/tmt-newswire/globenewswire/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2382605", "source_name": "The Manila Times", "published_at": "2026-07-11T19:39:53", "published_display": "11 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Global\u2019s BridgeBio Pharma (NASDAQ: BBIO) stake moves just under 5%", "summary": "Viking Global Investors and its affiliated entities have reported that their beneficial ownership in BridgeBio Pharma (NASDAQ: BBIO) has fallen just under 5%, specifically to 4.9951% as of July 9, 2026. This change was disclosed in an Amendment No. 12 to their Schedule 13D filing", "url": "https://www.stocktitan.net/sec-filings/BBIO/schedule-13d-a-bridge-bio-pharma-inc-amended-major-shareholder-report-c7bd1b05c571.html", "source_name": "Stock Titan", "published_at": "2026-07-11T13:09:43", "published_display": "11 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio (BBIO) Q1 2025 earnings summary", "summary": "BridgeBio's Q1 2025 results show strong initial sales for Attruby and significant total revenue. The company reported a widened net loss due to increased SG&A and interest expenses but maintains a robust pipeline with several phase three readouts expected within the next year. Wi", "url": "https://quartr.com/events/bridgebio-pharma-inc-bbio-q1-2025_3PPZGPUJ", "source_name": "Quartr", "published_at": "2026-07-11T00:40:57", "published_display": "11 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio hands new hires 83,283 stock-unit incentive awards", "summary": "BridgeBio Pharma (Nasdaq: BBIO) reported that its board compensation committee approved inducement equity grants of restricted stock units (RSUs) to 37 new employees, totaling 83,283 common shares, on July 7, 2026. These RSUs will vest one-fourth on August 16, 2027, with the rema", "url": "https://www.stocktitan.net/news/BBIO/bridge-bio-pharma-reports-inducement-grants-under-nasdaq-listing-i3iu9i3rwvsv.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:39:13", "published_display": "10 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High", "summary": "BridgeBio Pharma's (BBIO) stock surged to a 52-week high after AstraZeneca's (AZN) late-stage clinical trial for its ATTR-CM drug, Wainua, failed to meet its primary endpoint. This setback is seen as beneficial for BridgeBio's Attruby, its sole marketed drug for ATTR-CM, strength", "url": "https://www.tradingview.com/news/zacks:b3374f1cf094b:0-how-a-rival-s-clinical-setback-sent-bbio-stock-to-a-52-week-high/", "source_name": "TradingView", "published_at": "2026-07-10T16:39:13", "published_display": "10 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Is Up 16.8% After Phase 3 Infigratinib Win And $934M Raise", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/bridgebio-pharma-bbio-16-8-121349835.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T12:13:49+00:00", "published_display": "10 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?", "summary": "BridgeBio Pharma (BBIO) is experiencing a powerful transition, with its lead drug Attruby driving significant revenue growth and three more drugs in the pipeline. Despite a high market valuation and lack of profitability, the company is well-capitalized to pursue its ambitious la", "url": "https://www.trefis.com/stock/bbio/articles/606603/beyond-the-breakout-drug-is-bridgebio-pharma-stock-a-buy-on-its-next-act/2026-07-10", "source_name": "Trefis", "published_at": "2026-07-10T12:39:13", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNUjlDNWpKRXFJX0tSMm1WMWJMYmFLa09lcXFCLUpacmFNNG1fVjdWU2d5M3lRN2laWjFHWDFNWlFlY2twMHRWQTBDYVoyZU42ZkVQQ0ZpamhyMHl2S1Ziek1ldnl3aG9wVGg1RDlCVnVVS3hzTFZqRTVneGUyaDlfOHlFal9ScGdsWnV1eVNFcGQ0eFRkWG5IUzNyQQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T09:33:00+00:00", "published_display": "10 Jul 2026 09:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio (BBIO) Q3 2025 earnings summary", "summary": "BridgeBio (BBIO) reported strong Q3 2025 earnings, with total revenue reaching $120.7 million, primarily driven by the successful commercial launches of Attruby and Beyonttra. The company maintained a robust financial position with $645.9 million in cash and plans for NDA filings", "url": "https://quartr.com/events/bridgebio-pharma-inc-bbio-q3-2025_3PPZGpsg", "source_name": "Quartr", "published_at": "2026-07-10T02:39:13", "published_display": "10 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio stock jumps after rival heart drug fails key trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNUnhHaGczS3JXemNJejFpV2NxTjRuQW5Zc0NLUmhmSUZIbFdBUHo2ZGt1TnFFY1BkVDJtd0xmMGt0TEVtRDhKN1NlTDNoMGpYYTdHbUZScnRGZVQ4UVVJd055cU4wdGdVUnJZak5VTGlfTUxkczh6ZU5UdnR5aFY5RThacGNxQjZXaEd5OVNOMXJWcUIyRWRpN2hB?oc=5", "source_name": "Market source", "published_at": "2026-07-09T23:38:00+00:00", "published_display": "09 Jul 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma BBIO Jumps As Infigratinib Data, $1B Raise Fire Up Bulls", "summary": "BridgeBio Pharma (BBIO) shares surged over 15% following positive Phase 3 trial results for its drug infigratinib in pediatric achondroplasia, which also secured publication in the New England Journal of Medicine. The company plans FDA and EMA filings in 2026 for a potential U.S.", "url": "https://www.timothysykes.com/news/bridgebio-pharma-inc-bbio-news-2026_07_09-3/", "source_name": "www.timothysykes.com", "published_at": "2026-07-09T20:43:55", "published_display": "09 Jul 2026 20:43", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] BridgeBio Pharma, Inc. SEC Filing", "summary": "This article announces a Form 144 SEC filing by BridgeBio Pharma, Inc. (BBIO). The filing details a proposed sale of 17,167 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,442,028. The shares were acquired on J", "url": "https://www.stocktitan.net/sec-filings/BBIO/144-bridge-bio-pharma-inc-sec-filing-615bd79faaa2.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:43:55", "published_display": "09 Jul 2026 19:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma BBIO Jumps On Trial Win And $1B Raise", "summary": "BridgeBio Pharma (BBIO) shares jumped over 13% following positive Phase 3 clinical trial results for its oral infigratinib in pediatric achondroplasia, which showed statistically significant improvements in body proportionality and arm span. The company also secured up to $1 bill", "url": "https://stockstotrade.com/news/bridgebio-pharma-inc-bbio-news-2026_07_09-2/", "source_name": "StocksToTrade", "published_at": "2026-07-09T16:43:55", "published_display": "09 Jul 2026 16:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma stock reaches all-time high at 86.0 USD", "summary": "BridgeBio Pharma Inc. (BBIO) stock hit an all-time high of $86.00, pushing its market capitalization to $15.4 billion, reflecting a significant 69.29% increase over the past year. This milestone comes after recent developments including a $1 billion preferred equity investment an", "url": "https://www.investing.com/news/company-news/bridgebio-pharma-stock-reaches-alltime-high-at-860-usd-93CH-4784266", "source_name": "Investing.com", "published_at": "2026-07-09T14:43:55", "published_display": "09 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma Up Over 14%, on Track for Record High Close -- Data Talk", "summary": "BridgeBio Pharma's stock is up over 14% and is on track for a record high close. This significant jump suggests positive market reaction, likely driven by recent company developments or news.", "url": "https://www.moomoo.com/news/post/72722637/bridgebio-pharma-up-over-14-on-track-for-record-high", "source_name": "Moomoo", "published_at": "2026-07-09T13:43:55", "published_display": "09 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) Is Up 5.1% After Kidney Data Boost Attruby And Infigratinib Advances", "summary": "BridgeBio Pharma reported positive Phase 3 data for infigratinib and new post-hoc analyses suggesting kidney-protective effects of acoramidis (Attruby), alongside securing up to $1 billion in preferred equity financing. These developments aim to expand Attruby\u2019s profile and advan", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/bridgebio-pharma-bbio-is-up-51-after-kidney-data-boost-attru/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-09T13:43:55", "published_display": "09 Jul 2026 13:43", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback", "summary": "Shares of BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) surged by approximately 15% and 18%, respectively, after AstraZeneca's (AZN) and Ionis Pharma's (IONS) late-stage trial for a competing transthyretin amyloid cardiomyopathy (ATTR-CM) treatment failed. This setback for ri", "url": "https://www.gurufocus.com/news/8951118/bridgebio-pharma-bbio-and-alnylam-pharma-alny-surge-after-astrazeneca-trial-setback", "source_name": "GuruFocus", "published_at": "2026-07-09T12:27:46", "published_display": "09 Jul 2026 12:27", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, BridgeBio Pharma Lead", "summary": "S&P 500 futures are rising in premarket trading, with Alnylam Pharmaceuticals (ALNY) and BridgeBio Pharma (BBIO) leading the gains. ALNY was up 18.4% and BBIO was up 14.0% ahead of the U.S. stock market open.", "url": "https://www.barrons.com/articles/s-p-500-futures-climb-in-premarket-trading-alnylam-pharmaceuticals-bridgebio-pharma-lead-504d6635", "source_name": "Barron's", "published_at": "2026-07-09T11:39:46", "published_display": "09 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is BridgeBio Pharma stock surging today?", "summary": "BridgeBio Pharma's stock surged 12.4% after a rival heart disease drug from AstraZeneca and Ionis, Wainua, failed its Phase III trial. This failure provides a significant competitive advantage to BridgeBio's oral TTR stabilizer, Attruby, in the ATTR-CM market and reinforces Bridg", "url": "https://www.investing.com/news/stock-market-news/why-is-bridgebio-pharma-stock-surging-today-93CH-4783470", "source_name": "Investing.com", "published_at": "2026-07-09T10:39:46", "published_display": "09 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth", "summary": "BridgeBio Pharma (BBIO) is focusing on rare diseases with a strategy built around new diagnoses and targeted treatments. Its primary revenue driver, Attruby, has seen strong sales and benefits from increased awareness of transthyretin amyloid cardiomyopathy. The company's late-st", "url": "https://www.tradingview.com/news/zacks:ba7af4ddc094b:0-bridgebio-stock-taps-rare-disease-trends-and-new-diagnosis-growth/", "source_name": "TradingView", "published_at": "2026-07-08T16:11:05", "published_display": "08 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts", "summary": "BridgeBio Pharma's (BBIO) stock outlook is transitioning from a launch-focused narrative to one centered on broad commercial execution. Its primary revenue driver, Attruby, generated significant sales in its first full year and continues to grow, while the company plans three new", "url": "https://www.tradingview.com/news/zacks:ef91b97d7094b:0-bridgebio-stock-outlook-hinges-on-attruby-new-drug-catalysts/", "source_name": "TradingView", "published_at": "2026-07-08T16:11:05", "published_display": "08 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "9 Green Days In A Row: BridgeBio Pharma Stock Is Up 14%", "summary": "BridgeBio Pharma (BBIO) stock has experienced a nine-day winning streak, gaining 13.5% and adding $1.8 billion to its market value. Despite this momentum and 355.2% revenue growth, the biotech company shows deep losses with an operating margin of -86.9% and a negative P/E multipl", "url": "https://www.trefis.com/stock/bbio/articles/606162/9-green-days-in-a-row-bridgebio-pharma-stock-is-up-14/2026-07-08", "source_name": "Trefis", "published_at": "2026-07-08T10:10:25", "published_display": "08 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio gets $1B from Sixth Street, HCRx for three launches", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNMXBMMkV5V1gxaFJXckFOUHByNXVORG5PcUZ3dUZ0TlMwWmplWVhnSWJUQ2VUeE5DWjk1QWNNb2dRMG5neXIzTUJ2T3lEZlVHRWVKZkNQeVEyWDlaQzFFbWgwYzJad0kyZTFJcW5jVHRUT3dhS1dYbWsyZ1I3Qjc5djlOSF9jX3otV25wRG5iOWZ0ME5iVFpWeTFyMFJSZTBnNzNsdUlNYnVEY0V6QzJLMWNOX1FpRWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is BridgeBio Pharma (BBIO) Undervalued As Rare Disease Launch Hopes Face A Rich P/S?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Priority Review Puts BBP-418 And Valuation In Investor Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQUk5laEc1ZXFveDlrall4VTQ1TkY1TV8teU14VTE2RzBVZlZLbUNOcE5SSksybGRjdHZtd0JWcHNFNDF1NWtXd21RUE9lbUgyVjgtRlc5Y0NPNVJIZjJDc2syMElNaFpla3pad2xMbURDY2YxaXVLR0owMThmN2JaM0NmYklsOWl6bEpfQUx0YzlNbVJjQlQ3OGlfVDk2d05EZ1ctaXlVeWFLWFpTd3ZEd3Jkbzd4Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPYXkxMFAzRUI0MHVHeS1nbWVVd3V2YVZ5cmk2TW0tUzFjZzB4N2JseHp4VFFMQ1FvTXAwdGZodkpWeHFjZVNkTXNpTVNhMUwtanRwSnhWbUtuRkJuOHUydHBJVVVlU2IzazF1aXIzZ2MxS0c3RkpJYzBKb3dhdmphcm1hZ1lXaDFaZ0k0alNtSnJGU0NRQmNnV2R6eVllTU1MZW1jUUZOWmdnRkVTUThRY1dVSVZEdUVPSFlkWGVhdFBVWkZ1eHhmZg?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At BridgeBio Pharma (BBIO) Valuation After Recent Trading Weakness And Pipeline Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPYjVOTDNzcjNHVmZuWW5qcUhRVlhsYWZpQXVvZ1pYLU5DY3hEOWhpRU1BaFVURVhaM0xEeF96UEF4Smt4bUNZdkwtbWdpdXloejJZb0FfLW1QU0xpQUpJYVpJQkJ4ZzZxTE1Bb1pvTHdYTWhTUFdsZTF0aDBnS2wxNDFuUjh6ZGh0ckxHZEg3eDFlM2g5MzJMSjJFbENwc0VnU0xr?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brazil approves BridgeBio\u2019s acoramidis for heart condition", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNVDVJZ2ZOZV9kOUZqb1pjdGloVHZGYUg2WGVMb09BUFR5R3NzakdBRUJ6cE9NYXVhdnpJaWFtbnZoM1l2YzBKV3ZoVFRZLWMwVlRJZUNFWmFkYkljNWhTZU1CZTI1MFRxcng1M1NIUFlkcU9xRzlaaEZjM1hZMGpMdDNDN3V4Sml6WEVJNkgxVUhxbUd3dXBhaEwtR3VZMTFaQk1Gc3Nnc2Y5ZlNQdnRTMlFaSWI?oc=5", "source_name": "Investing.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA raises BridgeBio Pharma stock price target on Pfizer settlement clarity", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVkZjVlpudHRBREVoMHRocUhPUXEzbG5RQ1FXUDVKQ05BUlJKRWZqM2x1S0o2TmdXZ214UHphcy11RkpRYVB6eEdJNUhjVjR0T3JLWEhBR29oWm1NWUZTMjBra19jcEx0U1BYdlhvM3U1bWctZVpEVVFlRTRqMk9rTDh2eGl6VXgxVDN1ZlE0Mi00cS1OMjFzU2ZIYm9zWnBYUDFURVczMi1fc2JidVg3Ql9JS3JnNHc1V2swclV3ZkI0cm9UQXF3N2xtMEZZaklsR2c?oc=5", "source_name": "Investing.com", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has BridgeBio Pharma (BBIO) Run Too Far After 112% One Year Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BoFA Notes BridgeBio Pharma, Inc. (BBIO)\u2019s Upcoming Q4 Earnings May Have Limited Market Impact", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNWWo5YjNhOHVTVENHS2lJVE9VRlRIRTVPM0NYaW5ZSC1BRlVqcVQwbXVfai1yc3FUVkhqX3ItOXRYWkg3ZGM5TFM2TXFNa0R0VmpFRmdvYmFjTmZFVnBuLUdGclFuMFVwZWpfbnVoZDhQZy1Hc1JGTGJOLXd1TDRLcHZpcw?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BridgeBio Has More Room To Run (NASDAQ:BBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9MV2FXcV84YktmSDFSYXFLZUE0bVFwb1JmbTJYcVhZTUQxQ1MyWTVfVGhaSU5SeHBDcUN6S09NQVlQakhHNDR3bnZ2Y3lKQ0RrY0pFYTBSUjRQN21wTXFDejBXMTItSUQ1bjZqN1RCVkZVMFA0SW1qOUc3MA?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 52, "sentiment_summary": {"positive": 21, "negative": 3, "neutral": 28, "score": 60, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.1, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 85.89, "latest_week": "2026-07-10", "one_week_move": 11.3, "four_week_move": 28.6, "twelve_week_move": 11.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.29041, "market_dynamics_buy_signal": false, "relative_strength": 12.969785, "fair_value_gap": 102.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.8468, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+11.3% over one week, +28.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 71, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+11.3% over one week, +28.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BBIO6017175 Bond Risk Profile"}], "updated_at": "2026-07-16T09:44:04.678055+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}